Metastatic Melanoma - Pipeline Review, H2 2014
Summary
Global Markets Direct’s, ‘Metastatic Melanoma - Pipeline Review, H2 2014’, provides an overview of the Metastatic Melanoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Melanoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Melanoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
Introduction 6
Metastatic Melanoma Overview 7
Therapeutics Development 8
Metastatic Melanoma - Therapeutics under Development by Companies 10
Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Melanoma - Pipeline Products Glance 19
Metastatic Melanoma - Products under Development by Companies 22
Metastatic Melanoma - Products under Investigation by Universities/Institutes 29
Metastatic Melanoma - Companies Involved in Therapeutics Development 30
Metastatic Melanoma - Therapeutics Assessment 95
Drug Profiles 114
Metastatic Melanoma - Recent Pipeline Updates 333
Metastatic Melanoma - Dormant Projects 437
Metastatic Melanoma - Discontinued Products 440
Metastatic Melanoma - Product Development Milestones 441
Appendix 450
List Of Tables
List of Tables
Number of Products under Development for Metastatic Melanoma, H2 2014 22
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2014 23
Number of Products under Development by Companies, H2 2014 25
Number of Products under Development by Companies, H2 2014 (Contd..1) 26
Number of Products under Development by Companies, H2 2014 (Contd..2) 27
Number of Products under Development by Companies, H2 2014 (Contd..3) 28
Number of Products under Development by Companies, H2 2014 (Contd..4) 29
Number of Products under Development by Companies, H2 2014 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H2 2014 32
Comparative Analysis by Late Stage Development, H2 2014 33
Comparative Analysis by Clinical Stage Development, H2 2014 34
Comparative Analysis by Early Stage Development, H2 2014 35
Products under Development by Companies, H2 2014 36
Products under Development by Companies, H2 2014 (Contd..1) 37
Products under Development by Companies, H2 2014 (Contd..2) 38
Products under Development by Companies, H2 2014 (Contd..3) 39
Products under Development by Companies, H2 2014 (Contd..4) 40
Products under Development by Companies, H2 2014 (Contd..5) 41
Products under Development by Companies, H2 2014 (Contd..6) 42
Products under Investigation by Universities/Institutes, H2 2014 43
Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 44
Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 45
Metastatic Melanoma - Pipeline by Vical Incorporated, H2 2014 46
Metastatic Melanoma - Pipeline by Amgen Inc., H2 2014 47
Metastatic Melanoma - Pipeline by Sanofi, H2 2014 48
Metastatic Melanoma - Pipeline by AstraZeneca PLC, H2 2014 49
Metastatic Melanoma - Pipeline by GlaxoSmithKline plc, H2 2014 50
Metastatic Melanoma - Pipeline by Genentech, Inc., H2 2014 51
Metastatic Melanoma - Pipeline by Agenus, Inc., H2 2014 52
Metastatic Melanoma - Pipeline by MedImmune, LLC, H2 2014 53
Metastatic Melanoma - Pipeline by Merck & Co., Inc., H2 2014 54
Metastatic Melanoma - Pipeline by Plexxikon Inc., H2 2014 55
Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H2 2014 56
Metastatic Melanoma - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 57
Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 58
Metastatic Melanoma - Pipeline by Novartis AG, H2 2014 59
Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H2 2014 60
Metastatic Melanoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 61
Metastatic Melanoma - Pipeline by Pfizer Inc., H2 2014 62
Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 63
Metastatic Melanoma - Pipeline by Celgene Corporation, H2 2014 64
Metastatic Melanoma - Pipeline by Bayer AG, H2 2014 65
Metastatic Melanoma - Pipeline by Incyte Corporation, H2 2014 66
Metastatic Melanoma - Pipeline by Merck KGaA, H2 2014 67
Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H2 2014 68
Metastatic Melanoma - Pipeline by Momenta Pharmaceuticals, Inc., H2 2014 69
Metastatic Melanoma - Pipeline by AVAX Technologies, Inc., H2 2014 70
Metastatic Melanoma - Pipeline by Bionomics Limited, H2 2014 71
Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H2 2014 72
Metastatic Melanoma - Pipeline by NeoStem, Inc., H2 2014 73
Metastatic Melanoma - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 74
Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H2 2014 75
Metastatic Melanoma - Pipeline by Takara Bio Inc., H2 2014 76
Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 77
Metastatic Melanoma - Pipeline by Galapagos NV, H2 2014 78
Metastatic Melanoma - Pipeline by PCI Biotech AS, H2 2014 79
Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H2 2014 80
Metastatic Melanoma - Pipeline by Morphotek, Inc., H2 2014 81
Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H2 2014 82
Metastatic Melanoma - Pipeline by Colby Pharmaceutical Company, H2 2014 83
Metastatic Melanoma - Pipeline by Philogen S.p.A., H2 2014 84
Metastatic Melanoma - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 85
Metastatic Melanoma - Pipeline by Affichem, H2 2014 86
Metastatic Melanoma - Pipeline by Polyphor Ltd., H2 2014 87
Metastatic Melanoma - Pipeline by Omeros Corporation, H2 2014 88
Metastatic Melanoma - Pipeline by ImmuRx, Inc., H2 2014 89
Metastatic Melanoma - Pipeline by Immune Design Corp., H2 2014 90
Metastatic Melanoma - Pipeline by SBI Biotech Co., Ltd., H2 2014 91
Metastatic Melanoma - Pipeline by AB Science, H2 2014 92
Metastatic Melanoma - Pipeline by CureTech Ltd., H2 2014 93
Metastatic Melanoma - Pipeline by WntResearch AB, H2 2014 94
Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H2 2014 95
Metastatic Melanoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2014 96
Metastatic Melanoma - Pipeline by n.v. BRUCELLS s.a., H2 2014 97
Metastatic Melanoma - Pipeline by Cavion LLC, H2 2014 98
Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H2 2014 99
Metastatic Melanoma - Pipeline by Immunophotonics Inc, H2 2014 100
Metastatic Melanoma - Pipeline by Kite Pharma, Inc., H2 2014 101
Metastatic Melanoma - Pipeline by Sanofi Pasteur SA, H2 2014 102
Metastatic Melanoma - Pipeline by OncoSec Medical Inc., H2 2014 103
Metastatic Melanoma - Pipeline by Vaxeal Holding SA, H2 2014 104
Metastatic Melanoma - Pipeline by Bioncotech Therapeutics S.L., H2 2014 105
Metastatic Melanoma - Pipeline by AbbVie Inc., H2 2014 106
Metastatic Melanoma - Pipeline by Ultimovacs AS, H2 2014 107
Metastatic Melanoma - Pipeline by Agalimmune Ltd, H2 2014 108
Assessment by Monotherapy Products, H2 2014 109
Assessment by Combination Products, H2 2014 110
Number of Products by Stage and Target, H2 2014 113
Number of Products by Stage and Mechanism of Action, H2 2014 119
Number of Products by Stage and Route of Administration, H2 2014 124
Number of Products by Stage and Molecule Type, H2 2014 127
Metastatic Melanoma Therapeutics - Recent Pipeline Updates, H2 2014 347
Metastatic Melanoma - Dormant Projects, H2 2014 451
Metastatic Melanoma - Discontinued Products, H2 2014 454
List Of Figures
List of Figures
Number of Products under Development for Metastatic Melanoma, H2 2014 22
Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H2 2014 23
Number of Products under Development by Companies, H2 2014 24
Number of Products under Investigation by Universities/Institutes, H2 2014 31
Comparative Analysis by Late Stage Development, H2 2014 33
Comparative Analysis by Clinical Stage Development, H2 2014 34
Comparative Analysis by Early Stage Products, H2 2014 35
Assessment by Monotherapy Products, H2 2014 109
Assessment by Combination Products, H2 2014 110
Number of Products by Top 10 Target, H2 2014 111
Number of Products by Stage and Top 10 Target, H2 2014 112
Number of Products by Top 10 Mechanism of Action, H2 2014 117
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 118
Number of Products by Top 10 Route of Administration, H2 2014 123
Number of Products by Stage and Top 10 Route of Administration, H2 2014 124
Number of Products by Top 10 Molecule Type, H2 2014 125
Number of Products by Stage and Top 10 Molecule Type, H2 2014 126
